Biomerica (NASDAQ:BMRA) released its quarterly earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative net margin of 52.42% and a negative return on equity of 40.08%.
Shares of Biomerica stock traded down $0.36 on Friday, hitting $5.70. 419,885 shares of the company’s stock traded hands, compared to its average volume of 1,561,208. Biomerica has a one year low of $2.05 and a one year high of $23.39. The company has a fifty day moving average of $5.75 and a two-hundred day moving average of $7.05. The company has a market capitalization of $66.99 million, a price-to-earnings ratio of -17.66 and a beta of -0.47.
A number of equities research analysts have commented on BMRA shares. Colliers Securities started coverage on Biomerica in a research report on Tuesday, November 10th. They issued a “buy” rating and a $13.00 price target on the stock. B. Riley reduced their price target on Biomerica from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Aegis cut their target price on Biomerica from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, October 19th.
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Recommended Story: Buyback
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.